X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (13) 13
index medicus (13) 13
female (9) 9
human necessities (8) 8
hygiene (8) 8
medical or veterinary science (8) 8
middle aged (8) 8
preparations for medical, dental, or toilet purposes (8) 8
cardiac & cardiovascular systems (7) 7
double-blind method (7) 7
pcsk9 (7) 7
specific therapeutic activity of chemical compounds ormedicinal preparations (7) 7
alirocumab (6) 6
antibodies, monoclonal - adverse effects (6) 6
atorvastatin (6) 6
cholesterol (6) 6
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (6) 6
male (6) 6
monoclonal-antibody (6) 6
risk factors (6) 6
antibodies, monoclonal - therapeutic use (5) 5
cardiology and cardiovascular medicine (5) 5
cardiovascular (5) 5
cholesterol, ldl - blood (5) 5
ezetimibe (5) 5
hypercholesterolemia - drug therapy (5) 5
statins (5) 5
anticholesteremic agents - adverse effects (4) 4
care and treatment (4) 4
density-lipoprotein cholesterol (4) 4
diabetes (4) 4
human papillomavirus (4) 4
hypercholesterolemia (4) 4
low density lipoproteins (4) 4
monoclonal antibodies (4) 4
therapy (4) 4
treatment outcome (4) 4
abridged index medicus (3) 3
adult (3) 3
antibodies, monoclonal - administration & dosage (3) 3
cardiovascular disease (3) 3
cardiovascular diseases (3) 3
cardiovascular diseases - prevention & control (3) 3
clinical trials (3) 3
dna (3) 3
drug therapy (3) 3
drug therapy, combination (3) 3
evolocumab (3) 3
follow-up studies (3) 3
heart attacks (3) 3
heterozygous familial hypercholesterolemia (3) 3
hypercholesterolemia - blood (3) 3
hyperlipoproteinemia type ii - drug therapy (3) 3
intraepithelial neoplasia (3) 3
laboratories (3) 3
ldl cholesterol (3) 3
ldl-c (3) 3
pathology (3) 3
pharmacology & pharmacy (3) 3
studies (3) 3
uterine cervical neoplasms - virology (3) 3
9 serine-protease (2) 2
aged (2) 2
analysis (2) 2
anticholesteremic agents - administration & dosage (2) 2
anticholesteremic agents - therapeutic use (2) 2
cancer (2) 2
cardiology (2) 2
cardiovascular agents (2) 2
cardiovascular-risk patients (2) 2
cervical intraepithelial neoplasia - virology (2) 2
cervix uteri - virology (2) 2
chi-square distribution (2) 2
cholesterol, ldl - metabolism (2) 2
controlled-trial (2) 2
design (2) 2
diagnosis (2) 2
dosage and administration (2) 2
dose-response relationship, drug (2) 2
drug administration schedule (2) 2
efficacy (2) 2
ezetimibe - adverse effects (2) 2
genetic aspects (2) 2
genotypes (2) 2
guidelines (2) 2
human-papillomavirus infection (2) 2
hypercholesterolemia - complications (2) 2
hyperlipoproteinemia type ii - blood (2) 2
image cytometry (2) 2
immunohistochemistry (2) 2
infection (2) 2
internal medicine (2) 2
lipids (2) 2
low density lipoprotein (2) 2
low-density lipoprotein cholesterol (2) 2
maximum tolerated dose (2) 2
medicine & public health (2) 2
metaanalysis (2) 2
monoclonal antibody (2) 2
monotherapy (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


American Heart Journal, ISSN 0002-8703, 2015, Volume 169, Issue 6, pp. 906 - 915.e13
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2015, Volume 372, Issue 16, pp. 1489 - 1499
Journal Article
The American Journal of Cardiology, ISSN 0002-9149, 12/2016, Volume 118, Issue 12, pp. 1805 - 1811
Previous individual trials of alirocumab (a PCSK9 monoclonal antibody) showed significant low-density lipoprotein cholesterol reductions with overall... 
CARDIAC & CARDIOVASCULAR SYSTEMS | THERAPY | METAANALYSIS | EFFICACY | REDUCING LIPIDS | HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA | CARDIOVASCULAR-RISK PATIENTS | OUTCOMES | 9 SERINE-PROTEASE | EZETIMIBE | ATORVASTATIN | Back Pain - chemically induced | Myocardial Infarction - epidemiology | Humans | Middle Aged | Nasopharyngitis - chemically induced | Antibodies, Monoclonal - adverse effects | Coronary Disease - epidemiology | Hypercholesterolemia - drug therapy | Diabetes Mellitus, Type 2 - epidemiology | Clinical Trials, Phase III as Topic | Urinary Tract Infections - chemically induced | Respiratory Tract Infections - chemically induced | Stroke - epidemiology | Pruritus - chemically induced | Hypercholesterolemia - epidemiology | Acute Coronary Syndrome - epidemiology | Comorbidity | Ezetimibe - adverse effects | Angina, Unstable - epidemiology | Influenza, Human - chemically induced | Anticholesteremic Agents - adverse effects | Randomized Controlled Trials as Topic | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Aged | Clinical Trials, Phase II as Topic | Stroke (Disease) | Medical colleges | Analysis | Low density lipoproteins | Atherosclerosis | Monoclonal antibodies | Health aspects | Coronary heart disease | Antilipemic agents | Studies | Confidence intervals | FDA approval | Diabetes | Pruritus | Drug dosages | Patients | Index Medicus | Abridged Index Medicus
Journal Article
Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy, ISSN 0920-3206, 2016, Volume 30, Issue 5, pp. 473 - 483
Journal Article
Journal Article
Journal Article
European heart journal, ISSN 0195-668X, 2015, Volume 36, Issue 43, pp. 2996 - 3003
Journal Article
BMC cardiovascular disorders, ISSN 1471-2261, 2014, Volume 14, Issue 1, pp. 121 - 121
Background: Alirocumab is a fully human monoclonal antibody to proprotein convertase subtilisin kexin type 9 (PCSK9) under investigation for treatment of... 
Proprotein convertase subtilisin kexin type 9 | Alirocumab | Monoclonal antibody | Low-density lipoprotein cholesterol | Ezetimibe | CARDIAC & CARDIOVASCULAR SYSTEMS | SERUM-CHOLESTEROL | BLOOD CHOLESTEROL | GUIDELINES | INDIVIDUAL DATA | ATORVASTATIN | LDL CHOLESTEROL | DENSITY-LIPOPROTEIN CHOLESTEROL | THERAPY | DISEASE | CLINICAL-PRACTICE | Proprotein Convertases - antagonists & inhibitors | United States | Cardiovascular Diseases - prevention & control | Humans | Clinical Protocols | Antibodies, Monoclonal - therapeutic use | Cardiovascular Diseases - enzymology | Hypercholesterolemia - drug therapy | Serine Proteinase Inhibitors - therapeutic use | Time Factors | Hypercholesterolemia - enzymology | Serine Endopeptidases - immunology | Cardiovascular Diseases - blood | Cholesterol, LDL - blood | Drug Therapy, Combination | Cardiovascular Diseases - diagnosis | Cardiovascular Diseases - etiology | Hypercholesterolemia - blood | Double-Blind Method | Risk Assessment | Proprotein Convertases - metabolism | Risk Factors | Treatment Outcome | Biomarkers - blood | Proprotein Convertases - immunology | Maximum Tolerated Dose | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Hypercholesterolemia - diagnosis | Hypercholesterolemia - complications | Serine Endopeptidases - metabolism | Research Design | Proprotein Convertase 9 | Pharmaceutical industry | Product development | Studies | Cardiovascular disease | Heart attacks | Drug therapy | Cholesterol | Statins | Index Medicus
Journal Article
JACC (Journal of the American College of Cardiology), ISSN 0735-1097, 2015, Volume 65, Issue 10, pp. A1363 - A1363
  Placebo-controlled pool of Phase 3 Adjudicated cardiovascular events, % (n) N=2318 N=1174 Any patients with TEAE adjudicated CV event (CHD death, non-fatal... 
Cardiovascular | Internal Medicine | Clinical trials | Studies | Heart attacks | Laboratories | Cardiovascular disease | Hospitalization | Diabetes | Drug therapy | Cholesterol
Journal Article
JACC (Journal of the American College of Cardiology), ISSN 0735-1097, 2015, Volume 65, Issue 10, pp. A1350 - A1350
  Consequences of very low LDL-C levels are not well understood. [...]AE rates were examined in patients (pts) who achieved 2 consecutive calculated LDL-C <25... 
Cardiovascular | Internal Medicine | Clinical trials | Low density lipoproteins | Cholesterol | Infections | Pain | Diabetes | Laboratories | Low density lipoprotein
Journal Article
by Ray, Kausik K and Ray, Michael and Colhoun, Helen M and Szarek, Michael and Baccara-Dinet, Marie and Bhatt, Deepak L and Bittner, Vera A and Budaj, Andrzej J and Budaj, Andrzej and Diaz, Rafael and Diaz, Ariel and Goodman, Shaun G and Hanotin, Corinne and Harrington, Robert A and Jukema, J Wouter and Jukema, J. Wouter and Jukema, Johan and Loizeau, Virginie and Lopes, Renato D and Lopes, Renato and Moryusef, Angèle and Murin, Jan and Pordy, Robert and Ristic, Arsen D and Roe, Matthew T and Tuñón, José and White, Harvey D and White, Matthew and White, Lindsey and Zeiher, Andreas M and Schwartz, Steven and Schwartz, Michael and Schwartz, Gregory G and Steg, Philippe Gabriel and Steg, Ph. Gabriel and Tricoci, Pierluigi and Mahaffey, Kenneth W and Edelberg, Jay M and Lecorps, Guillaume and Sasiela, William J and Tamby, Jean-François and Aylward, Philip E and Drexel, Heinz and Sinnaeve, Peter and Dilic, Mirza and Gotcheva, Nina N and Prieto, Juan-Carlos and Prieto, Juan C and Yong, Huo and López-Jaramillo, Patricio and Pećin, Ivan and Reiner, Zeljko and Ostadal, Petr and Viigimaa, Margus and Nieminen, Markku S and Chumburidze, Vakhtang and Marx, Roger and Marx, Nikolaus and Danchin, Nicolas and Liberopoulos, Evangelos and Montenegro Valdovinos, Pablo Carlos and Tse, Hung-Fat and Kiss, Robert Gabor and Xavier, Denis and Zahger, Doron and Valgimigli, Marco and Kimura, Kazuo and Kimura, Takeshi and Kim, Sang-Hyun and Kim, Youngkwon and Kim, Chongjin and Kim, Hyo Soo and Kim, Hack-Lyoung and Kim, Moo Hyun and Kim, Hyo-Soo and Kim, Hae Young and Erglis, Andrejs and Laucevicius, Aleksandras and Kedev, Sasko and Yusoff, Khalid and Ramos López, Gabriel Arturo and Alings, Marco and Halvorsen, Sigrun and Correa Flores, Roger M and Morais, Joao and Dorobantu, Maria and Karpov, Yuri and Karpov, Yuriy and Chua, Terrance and Fras, Zlatko and Dalby, Anthony J and de Silva, H. Asita and Hagström, Emil and Landmesser, Ulf and Chiang, Chern-En and Sritara, Piyamitr and Guneri, Sema and Parkhomenko, Alexander and Moriarty, Patrick M and Moriarty, Katie and ... and ODYSSEY OUTCOMES Comm Investigato and ODYSSEY OUTCOMES Committees and Investigators
The Lancet Diabetes & Endocrinology, ISSN 2213-8587, 08/2019, Volume 7, Issue 8, pp. 618 - 628
After acute coronary syndrome, diabetes conveys an excess risk of ischaemic cardiovascular events. A reduction in mean LDL cholesterol to 1·4–1·8 mmol/L with... 
MYOCARDIAL-INFARCTION | LIRAGLUTIDE | STATIN THERAPY | BLOOD-GLUCOSE | GUIDELINES | ENDOCRINOLOGY & METABOLISM | RISK | PCSK9 | GENETIC-VARIANTS | ASSOCIATION | EVOLOCUMAB
Journal Article